Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

United States Influenza Vaccine Market 2016 Clinical Trials, Competitive Strategies and Forecast to 2022

Thursday, December 1, 2016 1:05
% of readers think this story is Fact. Add your two cents.

(Before It's News)

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

Request a sample report @

The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market. 

Major and Promising Vaccine covered in the report are as follows:

1. Fluzone High–Dose 
2. Fluzone Quadrivalent 
3. Intradermal (ID) Trivalent 
4. Vaxigrip 
5. Fluarix Quadrivalent 
6. Flulaval Quadrivalent 
7. Fluenz Tetra 
8. FluMist Quadrivalent 
9. Flublok 
10. VN–100 
11. M–001 
12. VAX–2012Q 
13. TAK – 850 
14. Flucelvax Quadrivalent 
15. Afluria Quadrivalent 
16. Agrippal 
17. Fluad 
18. Fluvirin 
19. Fluvax

Key Companies Covered in the Report are as follows

1. Sanofi Pasteur 
2. GlaxoSmithKline(GSK) 
3. Seqirus 
4. AstraZenecca 
5. Protein Sciences Corporation 
6. Novavax 
7. Daiichi–Sankyo 
8. Mitsubishi Tanabe Pharma 
9. BiondVax Pharmaceuticals Ltd 
10. VaxInnate

Complete report details @

Key points in table of content

1. Executive Summary

2. United States Influenza Vaccine Market & Forecast

3. United States Number of Persons Vaccinated with Influenza Vaccine 
    3.1 Number of Children Vaccinated 
    3.2 Number of Adults Vaccinated

4. United States Influenza Vaccine Market Drivers and Barriers 
    4.1 Market Drivers 
    4.2 Market Barriers

5. United States Influenza Vaccine Production & Distribution 
    5.1 Vaccine Choices Remain Available for Patients, Providers 
    5.2 Influenza Vaccine Price Trends 
      5.2.1 Pediatric Influenza Vaccine Price Trends 
      5.2.2 Adult Influenza Vaccine Price Trends 
    5.3 Influenza Vaccine Production, Supply, and Allocation 
    5.4 Influenza Vaccine Distribution & Demand 
    5.5 Influenza Vaccine Effectiveness 
    5.6 Managing Influenza with Diagnostic Resources 
    5.7 Distribution Method of Influenza Vaccination

6. United States Influenza Vaccine Market – Regulatory Landscape

7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations 
    7.1 Merger & Acquisitions 
    7.2 Collaboration Deal 
    7.3 Licensing, Exclusive & Distribution Agreement Deal 
      7.3.1 Licensing Agreement 
      7.3.2 Exclusive Agreement 
      7.3.3 Distribution Agreement

8. Influenza Vaccine – Pipeline Assessment 
    8.1 Promising Vaccine in Clinical Development 
    8.2 Promising Vaccine in Early–Stage Development

9. Influenza Vaccine – Clinical Trials Assessment by Phase and Trial Status 
    9.1 Year 2016 
    9.2 Year 2015 
    9.3 Year 2014 
    9.4 Year 2013

10. Key Companies Analysis 
    10.1 Sanofi Pasteur 
      10.1.1 Business Overview 
      10.1.2 Sanofi Pasteur – Influenza Vaccine Outlook 
 Fluzone High–Dose Vaccine 
 Fluzone Quadrivalent Vaccine 
 Intradermal (ID) Trivalent Influenza Vaccine 
 Vaxigrip Vaccine 
      10.1.3 Influenza Vaccine Sales Analysis 
    10.2 GlaxoSmithKline (GSK) 
      10.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook 
 Fluarix Quadrivalent 
 Flulaval Quadrivalent 
      10.2.2 Influenza Vaccine Sales Analysis & Forecast 
    10.3 AstraZeneca 
      10.3.1 Business Overview 
      10.3.2 AstraZeneca – Influenza Vaccine Outlook 
 Fluenz Tetra/FluMist Quadrivalent 
      10.3.3 Influenza Vaccine Sales Analysis 
    10.4 Protein Sciences Corporation 
      10.4.1 Business Overview 
      10.4.2 Protein Sciences Corporation – Influenza Vaccine Outlook 
    10.5 Seqirus (CSL Limited) 
      10.5.1 Business Overview 
      10.5.2 Seqirus – Influenza Vaccine Outlook 
 Flucelvax Quadrivalent 
 Afluria Quadrivalent 

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.